Which has preferable earnings and valuation, INVA or LGND?

Innoviva has higher revenue and earnings than Ligand Pharmaceuticals. Innoviva is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Innoviva $411.33M 4.04 $271.17M $6.01 3.74 Ligand Pharmaceuticals $268.09M 20.55 $124.45M $7.37 37.30

Does the media favor INVA or LGND?

In the previous week, Ligand Pharmaceuticals had 9 more articles in the media than Innoviva. MarketBeat recorded 10 mentions for Ligand Pharmaceuticals and 1 mentions for Innoviva. Innoviva's average media sentiment score of 0.67 beat Ligand Pharmaceuticals' score of 0.43 indicating that Innoviva is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innoviva 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ligand Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, CLDX or INVA?

Innoviva has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Celldex Therapeutics $1.54M 1,652.88 -$258.76M -$4.26 N/A Innoviva $411.33M 4.04 $271.17M $6.01 3.74

Does the media prefer CLDX or INVA?

In the previous week, Celldex Therapeutics had 2 more articles in the media than Innoviva. MarketBeat recorded 3 mentions for Celldex Therapeutics and 1 mentions for Innoviva. Innoviva's average media sentiment score of 0.67 beat Celldex Therapeutics' score of 0.38 indicating that Innoviva is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celldex Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Innoviva 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BCRX or INVA?

In the previous week, BioCryst Pharmaceuticals and BioCryst Pharmaceuticals both had 1 articles in the media. Innoviva's average media sentiment score of 0.67 beat BioCryst Pharmaceuticals' score of 0.00 indicating that Innoviva is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioCryst Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Innoviva 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, INVA or NVAX?

Novavax has higher revenue and earnings than Innoviva. Novavax is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Innoviva $411.33M 4.04 $271.17M $6.01 3.74 Novavax $596.34M 2.52 $440.30M -$0.58 N/A

Is INVA or NVAX more profitable?

Innoviva has a net margin of 119.89% compared to Novavax's net margin of -14.73%. Innoviva's return on equity of 33.33% beat Novavax's return on equity. Company Net Margins Return on Equity Return on Assets Innoviva 119.89% 33.33% 22.67% Novavax -14.73% -14.82% 1.23%

Does the media prefer INVA or NVAX?

In the previous week, Novavax had 4 more articles in the media than Innoviva. MarketBeat recorded 5 mentions for Novavax and 1 mentions for Innoviva. Innoviva's average media sentiment score of 0.67 beat Novavax's score of 0.33 indicating that Innoviva is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innoviva 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Novavax 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, INVA or ZBIO?

Innoviva has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Innoviva $411.33M 4.04 $271.17M $6.01 3.74 Zenas BioPharma $10M 124.87 -$377.74M -$8.47 N/A

Does the media prefer INVA or ZBIO?

In the previous week, Zenas BioPharma had 2 more articles in the media than Innoviva. MarketBeat recorded 3 mentions for Zenas BioPharma and 1 mentions for Innoviva. Zenas BioPharma's average media sentiment score of 1.33 beat Innoviva's score of 0.67 indicating that Zenas BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innoviva 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zenas BioPharma 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Innoviva (INVA) Competitors

$22.49 0.00 (0.00%)

Closing price 06/18/2026 04:00 PM Eastern

Extended Trading

$22.35 -0.14 (-0.63%)

As of 06/18/2026 07:56 PM Eastern

Compare

INVA vs. LGND, CLDX, BCRX, NVAX, and ZBIO

Should you buy Innoviva stock or one of its competitors? MarketBeat compares Innoviva with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Innoviva include Ligand Pharmaceuticals (LGND), Celldex Therapeutics (CLDX), BioCryst Pharmaceuticals (BCRX), Novavax (NVAX), and Zenas BioPharma (ZBIO). These companies are all part of the "biotechnology" industry.

How does Innoviva compare to Ligand Pharmaceuticals?

Innoviva (NASDAQ:INVA) and Ligand Pharmaceuticals (NASDAQ:LGND) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk.

In the previous week, Ligand Pharmaceuticals had 9 more articles in the media than Innoviva. MarketBeat recorded 10 mentions for Ligand Pharmaceuticals and 1 mentions for Innoviva. Innoviva's average media sentiment score of 0.67 beat Ligand Pharmaceuticals' score of 0.43 indicating that Innoviva is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innoviva	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ligand Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Innoviva has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market. Comparatively, Ligand Pharmaceuticals has a beta of 1.17, meaning that its share price is 17% more volatile than the broader market.

Innoviva has higher revenue and earnings than Ligand Pharmaceuticals. Innoviva is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$411.33M	4.04	$271.17M	$6.01	3.74
Ligand Pharmaceuticals	$268.09M	20.55	$124.45M	$7.37	37.30

Innoviva has a net margin of 119.89% compared to Ligand Pharmaceuticals' net margin of 55.95%. Innoviva's return on equity of 33.33% beat Ligand Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	119.89%	33.33%	22.67%
Ligand Pharmaceuticals	55.95%	16.19%	11.13%

99.1% of Innoviva shares are owned by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. 2.0% of Innoviva shares are owned by company insiders. Comparatively, 7.0% of Ligand Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Innoviva presently has a consensus target price of $36.20, suggesting a potential upside of 60.96%. Ligand Pharmaceuticals has a consensus target price of $257.71, suggesting a potential downside of 6.24%. Given Innoviva's higher possible upside, research analysts clearly believe Innoviva is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Ligand Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

Summary

Innoviva and Ligand Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Innoviva compare to Celldex Therapeutics?

Celldex Therapeutics (NASDAQ:CLDX) and Innoviva (NASDAQ:INVA) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

99.1% of Innoviva shares are held by institutional investors. 5.2% of Celldex Therapeutics shares are held by insiders. Comparatively, 2.0% of Innoviva shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Innoviva has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics	$1.54M	1,652.88	-$258.76M	-$4.26	N/A
Innoviva	$411.33M	4.04	$271.17M	$6.01	3.74

Innoviva has a net margin of 119.89% compared to Celldex Therapeutics' net margin of 0.00%. Innoviva's return on equity of 33.33% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics	N/A	-50.72%	-46.59%
Innoviva	119.89%	33.33%	22.67%

Celldex Therapeutics has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market. Comparatively, Innoviva has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market.

Celldex Therapeutics presently has a consensus target price of $49.30, indicating a potential upside of 52.02%. Innoviva has a consensus target price of $36.20, indicating a potential upside of 60.96%. Given Innoviva's higher possible upside, analysts plainly believe Innoviva is more favorable than Celldex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Celldex Therapeutics had 2 more articles in the media than Innoviva. MarketBeat recorded 3 mentions for Celldex Therapeutics and 1 mentions for Innoviva. Innoviva's average media sentiment score of 0.67 beat Celldex Therapeutics' score of 0.38 indicating that Innoviva is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celldex Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Innoviva	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Innoviva beats Celldex Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Innoviva compare to BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Innoviva (NASDAQ:INVA) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and media sentiment.

In the previous week, BioCryst Pharmaceuticals and BioCryst Pharmaceuticals both had 1 articles in the media. Innoviva's average media sentiment score of 0.67 beat BioCryst Pharmaceuticals' score of 0.00 indicating that Innoviva is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioCryst Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Innoviva	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioCryst Pharmaceuticals currently has a consensus target price of $20.70, indicating a potential upside of 130.26%. Innoviva has a consensus target price of $36.20, indicating a potential upside of 60.96%. Given BioCryst Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe BioCryst Pharmaceuticals is more favorable than Innoviva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.75
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Innoviva has lower revenue, but higher earnings than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCryst Pharmaceuticals	$874.84M	2.61	$263.86M	-$1.78	N/A
Innoviva	$411.33M	4.04	$271.17M	$6.01	3.74

85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.1% of Innoviva shares are owned by institutional investors. 3.8% of BioCryst Pharmaceuticals shares are owned by insiders. Comparatively, 2.0% of Innoviva shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

BioCryst Pharmaceuticals has a beta of 0.57, meaning that its stock price is 43% less volatile than the broader market. Comparatively, Innoviva has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market.

Innoviva has a net margin of 119.89% compared to BioCryst Pharmaceuticals' net margin of -51.71%. Innoviva's return on equity of 33.33% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%
Innoviva	119.89%	33.33%	22.67%

Summary

Innoviva beats BioCryst Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Innoviva compare to Novavax?

Innoviva (NASDAQ:INVA) and Novavax (NASDAQ:NVAX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.

Innoviva has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market. Comparatively, Novavax has a beta of 2.45, indicating that its share price is 145% more volatile than the broader market.

Innoviva has a net margin of 119.89% compared to Novavax's net margin of -14.73%. Innoviva's return on equity of 33.33% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	119.89%	33.33%	22.67%
Novavax	-14.73%	-14.82%	1.23%

Novavax has higher revenue and earnings than Innoviva. Novavax is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$411.33M	4.04	$271.17M	$6.01	3.74
Novavax	$596.34M	2.52	$440.30M	-$0.58	N/A

Innoviva presently has a consensus price target of $36.20, indicating a potential upside of 60.96%. Novavax has a consensus price target of $13.00, indicating a potential upside of 42.39%. Given Innoviva's stronger consensus rating and higher probable upside, research analysts plainly believe Innoviva is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Novavax	3 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.22

In the previous week, Novavax had 4 more articles in the media than Innoviva. MarketBeat recorded 5 mentions for Novavax and 1 mentions for Innoviva. Innoviva's average media sentiment score of 0.67 beat Novavax's score of 0.33 indicating that Innoviva is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innoviva	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Novavax	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

99.1% of Innoviva shares are held by institutional investors. Comparatively, 53.0% of Novavax shares are held by institutional investors. 2.0% of Innoviva shares are held by insiders. Comparatively, 1.6% of Novavax shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Innoviva beats Novavax on 11 of the 15 factors compared between the two stocks.

How does Innoviva compare to Zenas BioPharma?

Innoviva (NASDAQ:INVA) and Zenas BioPharma (NASDAQ:ZBIO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and valuation.

Innoviva has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -0.71, suggesting that its share price is 171% less volatile than the broader market.

Innoviva presently has a consensus target price of $36.20, indicating a potential upside of 60.96%. Zenas BioPharma has a consensus target price of $44.29, indicating a potential upside of 123.89%. Given Zenas BioPharma's higher possible upside, analysts plainly believe Zenas BioPharma is more favorable than Innoviva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

Innoviva has a net margin of 119.89% compared to Zenas BioPharma's net margin of 0.00%. Innoviva's return on equity of 33.33% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	119.89%	33.33%	22.67%
Zenas BioPharma	N/A	-99.99%	-58.06%

Innoviva has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$411.33M	4.04	$271.17M	$6.01	3.74
Zenas BioPharma	$10M	124.87	-$377.74M	-$8.47	N/A

99.1% of Innoviva shares are owned by institutional investors. 2.0% of Innoviva shares are owned by company insiders. Comparatively, 22.0% of Zenas BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Zenas BioPharma had 2 more articles in the media than Innoviva. MarketBeat recorded 3 mentions for Zenas BioPharma and 1 mentions for Innoviva. Zenas BioPharma's average media sentiment score of 1.33 beat Innoviva's score of 0.67 indicating that Zenas BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innoviva	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zenas BioPharma	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Innoviva beats Zenas BioPharma on 10 of the 16 factors compared between the two stocks.

Get Innoviva News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INVA vs. The Competition

Export

Metric	Innoviva	Large Cap Pharma Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.66B	$302.55B	$6.42B	$12.59B
Dividend Yield	N/A	2.85%	2.68%	5.81%
P/E Ratio	3.74	27.04	24.78	24.44
Price / Sales	4.04	4.99	532.71	109.74
Price / Cash	4.47	12.90	45.07	55.09
Price / Book	1.43	7.72	10.80	6.58
Net Income	$271.17M	$11.61B	$3.57B	$337.17M
7 Day Performance	-1.10%	-3.12%	0.72%	0.83%
1 Month Performance	1.31%	-1.95%	0.41%	2.25%
1 Year Performance	7.10%	18.96%	29.34%	36.14%

Innoviva Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INVA Innoviva	3.9022 of 5 stars	$22.49 flat	$36.20 +61.0%	+7.1%	$1.66B	$411.33M	3.74	100	News Coverage Gap Up
LGND Ligand Pharmaceuticals	2.4698 of 5 stars	$255.54 +0.4%	$257.71 +0.9%	+141.0%	$5.12B	$268.09M	34.67	80	Insider Trade Gap Down
CLDX Celldex Therapeutics	2.0104 of 5 stars	$31.27 +4.4%	$49.30 +57.7%	+58.2%	$2.45B	$1.54M	N/A	150
BCRX BioCryst Pharmaceuticals	2.2035 of 5 stars	$8.70 +2.4%	$20.70 +137.9%	-11.0%	$2.21B	$874.84M	N/A	530
NVAX Novavax	1.8186 of 5 stars	$8.88 -1.7%	$12.13 +36.5%	+42.4%	$1.46B	$1.12B	N/A	1,990	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INVA) was last updated on 6/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Innoviva (INVA) Competitors

INVA vs. LGND, CLDX, BCRX, NVAX, and ZBIO

How does Innoviva compare to Ligand Pharmaceuticals?

Summary

How does Innoviva compare to Celldex Therapeutics?

Summary

How does Innoviva compare to BioCryst Pharmaceuticals?

Summary

How does Innoviva compare to Novavax?

Summary

How does Innoviva compare to Zenas BioPharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INVA vs. The Competition

Innoviva Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Innoviva (INVA) Competitors

INVA vs. LGND, CLDX, BCRX, NVAX, and ZBIO

How does Innoviva compare to Ligand Pharmaceuticals?

Does the media favor INVA or LGND?

Which has more risk & volatility, INVA or LGND?

Which has preferable earnings and valuation, INVA or LGND?

Is INVA or LGND more profitable?

Do institutionals & insiders hold more shares of INVA or LGND?

Do analysts recommend INVA or LGND?

Summary

How does Innoviva compare to Celldex Therapeutics?

Do institutionals and insiders hold more shares of CLDX or INVA?

Which has better earnings & valuation, CLDX or INVA?

Is CLDX or INVA more profitable?

Which has more risk & volatility, CLDX or INVA?

Do analysts prefer CLDX or INVA?

Does the media prefer CLDX or INVA?

Summary

How does Innoviva compare to BioCryst Pharmaceuticals?

Does the media favor BCRX or INVA?

Do analysts prefer BCRX or INVA?

Which has preferable valuation & earnings, BCRX or INVA?

Do institutionals and insiders hold more shares of BCRX or INVA?

Which has more risk & volatility, BCRX or INVA?

Is BCRX or INVA more profitable?

Summary

How does Innoviva compare to Novavax?

Which has more volatility & risk, INVA or NVAX?

Is INVA or NVAX more profitable?

Which has stronger earnings & valuation, INVA or NVAX?

Do analysts prefer INVA or NVAX?

Does the media prefer INVA or NVAX?

Do institutionals and insiders have more ownership in INVA or NVAX?

Summary

How does Innoviva compare to Zenas BioPharma?

Which has more volatility & risk, INVA or ZBIO?

Do analysts rate INVA or ZBIO?

Is INVA or ZBIO more profitable?

Which has stronger earnings and valuation, INVA or ZBIO?

Do institutionals & insiders believe in INVA or ZBIO?

Does the media prefer INVA or ZBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INVA vs. The Competition

Innoviva Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools